Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 August 2007, Vol. 110, No. 3, pp. 833-839.
Prepublished online as a Blood First Edition Paper on April 11, 2007; DOI 10.1182/blood-2006-08-040121.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-08-040121v1
110/3/833    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kjeldsen-Kragh, J.
Right arrow Articles by Husebekk, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kjeldsen-Kragh, J.
Right arrow Articles by Husebekk, A.
Related Collections
Right arrow Clinical Trials and Observations
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia

Jens Kjeldsen-Kragh1,4, Mette Kjær Killie5,8, Geir Tomter1, Elzbieta Golebiowska1, Ingrid Randen1,4, Reidun Hauge1, Berit Aune6,9, Pål Øian6,9, Lauritz B. Dahl7,9, Jouko Pirhonen2,4, Rolf Lindeman3,4, Henrik Husby10, Guttorm Haugen10,12, Morten Grønn11, Bjørn Skogen5,8, and Anne Husebekk5,8

Departments of1 Immunology and Transfusion Medicine 2 Obstetrics and Gynecology, and 3 Pediatrics, Ullevål University Hospital, Oslo; 4 Faculty Division Ullevål University Hospital, University of Oslo, Oslo; Departments of5 Immunology and Transfusion Medicine 6 Obstetrics and Gynecology, and 7 Pediatrics, University Hospital of North Norway, Tromsø; Institutes of 8 Medical Biology and 9 Clinical Medicine, University of Tromsø, Tromsø; Departments of10 Obstetrics and Gynecology and 11 Pediatrics, Rikshospitalet-Radiumhospitalet Medical Center, Oslo; 12 Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway

The study's objective was to identify HPA 1a–negative women and to offer them an intervention program aimed to reduce morbidity and mortality of neonatal alloimmune thrombocytopenia (NAIT). HPA 1 typing was performed in 100 448 pregnant women. The HPA 1a–negative women were screened for anti–HPA 1a. In immunized women, delivery was performed by Cesarean section 2 to 4 weeks prior to term, with platelets from HPA 1a–negative donors reserved for immediate transfusion if petechiae were present and/or if platelet count was less than 35 x 109/L. Of the women screened, 2.1% were HPA 1a negative, and anti–HPA 1a was detected in 10.6% of these. One hundred seventy pregnancies were managed according to the intervention program, resulting in 161 HPA 1a–positive children. Of these, 55 had severe thrombocytopenia (< 50 x 109/L), including 2 with intracranial hemorrhage (ICH). One woman with a twin pregnancy missed the follow-up and had one stillborn and one severely thrombocytopenic live child. In 15 previous prospective studies (136 814 women) there were 51 cases of severe NAIT (3 intrauterine deaths and 7 with ICH). Acknowledging the limitation of comparing with historic controls, implementation of our screening and intervention program seemed to reduce the number of cases of severe NAIT-related complications from 10 of 51 to 3 of 57.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
C. Kaplan
Neonatal alloimmune thrombocytopenia
Haematologica, June 1, 2008; 93(6): 805 - 807.
[Full Text] [PDF]


Home page
haematolHome page
M. K. Killie, A. Husebekk, J. Kjeldsen-Kragh, and B. Skogen
A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn
Haematologica, June 1, 2008; 93(6): 870 - 877.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020